CXCL8 and COVID-19: Vilobelimab also appeared to reduce levels of the proinflammatory chemokine interleukin-8 (IL-8) in the phase 2 PANAMO trial [7], which plays a significant role in the pathogenesis of ARDS and likely COVID-19 as well [7, 17, 18].